Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.71
JNJ's Cash to Debt is ranked lower than
60% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.45 vs. JNJ: 1.71 )
Ranked among companies with meaningful Cash to Debt only.
JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 1.63 Max: 6.28
Current: 1.71
0.46
6.28
Equity to Asset 0.53
JNJ's Equity to Asset is ranked lower than
65% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. JNJ: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.67
Current: 0.53
0.5
0.67
Interest Coverage 41.02
JNJ's Interest Coverage is ranked higher than
57% of the 467 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.06 vs. JNJ: 41.02 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.54 Max: 208.73
Current: 41.02
28.29
208.73
F-Score: 6
Z-Score: 5.34
M-Score: -2.64
WACC vs ROIC
8.09%
26.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 25.89
JNJ's Operating margin (%) is ranked higher than
88% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. JNJ: 25.89 )
Ranked among companies with meaningful Operating margin (%) only.
JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 25.14 Max: 28.2
Current: 25.89
22.36
28.2
Net-margin (%) 21.92
JNJ's Net-margin (%) is ranked higher than
89% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.15 vs. JNJ: 21.92 )
Ranked among companies with meaningful Net-margin (%) only.
JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 21.99
Current: 21.92
14.87
21.99
ROE (%) 21.70
JNJ's ROE (%) is ranked higher than
85% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. JNJ: 21.70 )
Ranked among companies with meaningful ROE (%) only.
JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 30.17
Current: 21.7
17.02
30.17
ROA (%) 11.59
JNJ's ROA (%) is ranked higher than
82% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. JNJ: 11.59 )
Ranked among companies with meaningful ROA (%) only.
JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 17.08
Current: 11.59
8.93
17.08
ROC (Joel Greenblatt) (%) 88.45
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.16 vs. JNJ: 88.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 114.87
Current: 88.45
65.66
114.87
Revenue Growth (3Y)(%) 1.40
JNJ's Revenue Growth (3Y)(%) is ranked lower than
63% of the 602 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. JNJ: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.20 Max: 13.8
Current: 1.4
1.4
13.8
EBITDA Growth (3Y)(%) 9.30
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. JNJ: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 10.70 Max: 17.3
Current: 9.3
-6.6
17.3
EPS Growth (3Y)(%) 12.40
JNJ's EPS Growth (3Y)(%) is ranked higher than
59% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. JNJ: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 12.20 Max: 18.2
Current: 12.4
-8.6
18.2
» JNJ's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-14)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

JNJ Guru Trades in Q2 2015

David Dreman 6,648 sh (New)
Sarah Ketterer 1,207,926 sh (+41.27%)
John Rogers 782,026 sh (+19.02%)
Manning & Napier Advisors, Inc 3,292,140 sh (+17.49%)
Paul Tudor Jones 63,433 sh (+13.16%)
John Buckingham 63,439 sh (+2.51%)
Ruane Cunniff 77,357 sh (+1.87%)
Mairs and Power 2,158,264 sh (+1.86%)
Ken Fisher 10,641,756 sh (+1.77%)
Jeff Auxier 91,926 sh (+0.27%)
Richard Pzena 1,174,169 sh (+0.01%)
Michael Price 25,000 sh (unchged)
John Hussman 1,325 sh (unchged)
RS Investment Management 8,578 sh (unchged)
T Rowe Price Equity Income Fund 4,633,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Snow 3,270 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,632,757 sh (-0.28%)
First Eagle Investment 1,610,098 sh (-1.09%)
Murray Stahl 29,841 sh (-2.72%)
Jeremy Grantham 12,907,199 sh (-2.73%)
Tweedy Browne 3,918,801 sh (-3.38%)
PRIMECAP Management 11,370,350 sh (-4.12%)
Dodge & Cox 38,235 sh (-4.38%)
Mario Gabelli 315,150 sh (-5.40%)
Richard Perry 292,729 sh (-6.36%)
Yacktman Fund 3,500,000 sh (-10.26%)
Donald Yacktman 7,441,948 sh (-11.75%)
Yacktman Focused Fund 2,500,000 sh (-16.67%)
Pioneer Investments 2,068,266 sh (-21.14%)
Ray Dalio 194,993 sh (-27.27%)
» More
Q3 2015

JNJ Guru Trades in Q3 2015

John Burbank 32,624 sh (New)
Jim Simons 392,000 sh (New)
Charles Brandes 118,509 sh (New)
Chuck Royce 9,000 sh (New)
Louis Moore Bacon 63,428 sh (New)
Manning & Napier Advisors, Inc 4,406,762 sh (+33.86%)
Sarah Ketterer 1,593,359 sh (+31.91%)
RS Investment Management 10,457 sh (+21.90%)
Jeff Auxier 110,226 sh (+19.91%)
Pioneer Investments 2,381,190 sh (+15.13%)
John Rogers 884,154 sh (+13.06%)
Yacktman Focused Fund 2,600,000 sh (+4.00%)
Yacktman Fund 3,600,000 sh (+2.86%)
John Buckingham 64,896 sh (+2.30%)
Donald Yacktman 7,560,334 sh (+1.59%)
Tom Gayner 582,200 sh (+1.39%)
Murray Stahl 30,179 sh (+1.13%)
Mairs and Power 2,181,707 sh (+1.09%)
Mario Gabelli 317,847 sh (+0.86%)
T Rowe Price Equity Income Fund 4,672,800 sh (+0.86%)
Ken Fisher 10,689,483 sh (+0.45%)
Robert Olstein 71,000 sh (unchged)
John Hussman 1,325 sh (unchged)
David Carlson 460,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Richard Snow 3,270 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Perry 292,729 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Pzena 1,174,169 sh (unchged)
David Dreman Sold Out
Ruane Cunniff 76,400 sh (-1.24%)
Barrow, Hanley, Mewhinney & Strauss 15,399,839 sh (-1.49%)
First Eagle Investment 1,585,928 sh (-1.50%)
Tweedy Browne 3,855,936 sh (-1.60%)
Dodge & Cox 36,935 sh (-3.40%)
PRIMECAP Management 10,575,867 sh (-6.99%)
Jeremy Grantham 11,529,743 sh (-10.67%)
Ray Dalio 167,593 sh (-14.05%)
Paul Tudor Jones 47,878 sh (-24.52%)
» More
Q4 2015

JNJ Guru Trades in Q4 2015

Joel Greenblatt 39,586 sh (New)
John Hussman 26,325 sh (+1886.79%)
John Burbank 68,755 sh (+110.75%)
First Eagle Investment 3,032,177 sh (+91.19%)
Jim Simons 655,300 sh (+67.17%)
Pioneer Investments 3,824,174 sh (+60.60%)
Charles Brandes 151,094 sh (+27.50%)
Mario Gabelli 332,287 sh (+4.54%)
Tom Gayner 605,200 sh (+3.95%)
John Buckingham 65,746 sh (+1.31%)
Ken Fisher 10,815,964 sh (+1.18%)
Mairs and Power 2,184,308 sh (+0.12%)
Richard Pzena 1,174,524 sh (+0.03%)
Chuck Royce 9,000 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
T Rowe Price Equity Income Fund 4,672,800 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Carlson 460,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Louis Moore Bacon Sold Out
PRIMECAP Management 10,543,562 sh (-0.31%)
Richard Snow 3,260 sh (-0.31%)
Barrow, Hanley, Mewhinney & Strauss 15,342,046 sh (-0.38%)
Murray Stahl 29,941 sh (-0.79%)
Paul Tudor Jones 46,483 sh (-2.91%)
Donald Yacktman 7,316,129 sh (-3.23%)
Yacktman Focused Fund 2,500,000 sh (-3.85%)
Dodge & Cox 35,435 sh (-4.06%)
Tweedy Browne 3,693,349 sh (-4.22%)
Jeff Auxier 105,426 sh (-4.35%)
John Rogers 831,664 sh (-5.94%)
Sarah Ketterer 1,497,289 sh (-6.03%)
RS Investment Management 9,592 sh (-8.27%)
Jeremy Grantham 9,970,431 sh (-13.52%)
Manning & Napier Advisors, Inc 3,769,800 sh (-14.45%)
Ruane Cunniff 64,753 sh (-15.24%)
Ray Dalio 109,693 sh (-34.55%)
» More
Q1 2016

JNJ Guru Trades in Q1 2016

Jim Chanos 29,730 sh (New)
Diamond Hill Capital 1,969 sh (New)
David Rolfe 5,250 sh (New)
John Burbank 1,583,456 sh (+2203.04%)
Joel Greenblatt 242,043 sh (+511.44%)
Jim Simons 2,380,600 sh (+263.28%)
Murray Stahl 30,774 sh (+2.78%)
John Rogers 850,915 sh (+2.31%)
Mario Gabelli 337,588 sh (+1.60%)
Tom Gayner 610,800 sh (+0.93%)
Richard Pzena 1,185,329 sh (+0.92%)
Ken Fisher 10,854,263 sh (+0.35%)
Mairs and Power 2,185,213 sh (+0.04%)
Chuck Royce 9,000 sh (unchged)
Richard Snow 3,260 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Jim Chanos 5,952 sh (unchged)
Richard Perry 292,729 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Ray Dalio Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,327,465 sh (-0.10%)
Jeff Auxier 105,176 sh (-0.24%)
Dodge & Cox 34,808 sh (-1.77%)
Charles Brandes 146,253 sh (-3.20%)
John Buckingham 63,638 sh (-3.21%)
Donald Yacktman 7,080,500 sh (-3.22%)
Pioneer Investments 3,675,335 sh (-3.89%)
John Hussman 25,000 sh (-5.03%)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
Tweedy Browne 3,383,445 sh (-8.39%)
Sarah Ketterer 1,364,323 sh (-8.88%)
Jeremy Grantham 9,036,395 sh (-9.37%)
RS Investment Management 8,397 sh (-12.46%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
Robert Olstein 50,000 sh (-29.58%)
First Eagle Investment 1,142,872 sh (-62.31%)
Paul Tudor Jones 15,876 sh (-65.85%)
PRIMECAP Management 3,023,678 sh (-71.32%)
Ruane Cunniff 13,925 sh (-78.50%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. The brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. The brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO for the treatment of hepatitis C; INTELENCE and PREZISTA, treatments for HIV/AIDS; CONCERTA extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA/XEPLION, for the treatment of schizophrenia in adults; RISPERDAL CONSTA, for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE, a treatment for multiple myeloma; ZYTIGA, a treatment for metastatic castration-resistant prostate cancer; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT, to stimulate red blood cell production; and XARELTO, an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may cause to pulmonary embolism (PE) in patients undergoing hip or knee replace

Ratios

vs
industry
vs
history
P/E(ttm) 20.59
JNJ's P/E(ttm) is ranked higher than
65% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.44 vs. JNJ: 20.59 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 23.97
Current: 20.59
10.5
23.97
Forward P/E 16.03
JNJ's Forward P/E is ranked lower than
60% of the 90 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.95 vs. JNJ: 16.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.59
JNJ's PE(NRI) is ranked higher than
65% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.81 vs. JNJ: 20.59 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.67 Max: 23.94
Current: 20.59
10.5
23.94
Price/Owner Earnings (ttm) 18.38
JNJ's Price/Owner Earnings (ttm) is ranked higher than
74% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.19 vs. JNJ: 18.38 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JNJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.82  Med: 17.00 Max: 25.3
Current: 18.38
9.82
25.3
P/B 4.31
JNJ's P/B is ranked lower than
69% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. JNJ: 4.31 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.72 Max: 5.64
Current: 4.31
2.68
5.64
P/S 4.54
JNJ's P/S is ranked lower than
65% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. JNJ: 4.54 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 4.54
Current: 4.54
2.17
4.54
PFCF 21.76
JNJ's PFCF is ranked higher than
57% of the 199 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.71 vs. JNJ: 21.76 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.28  Med: 16.56 Max: 24.67
Current: 21.76
10.28
24.67
POCF 17.52
JNJ's POCF is ranked higher than
52% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.71 vs. JNJ: 17.52 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 8.98  Med: 13.22 Max: 18.36
Current: 17.52
8.98
18.36
EV-to-EBIT 15.94
JNJ's EV-to-EBIT is ranked higher than
64% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.64 vs. JNJ: 15.94 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.90 Max: 18.2
Current: 15.94
7.8
18.2
EV-to-EBITDA 13.28
JNJ's EV-to-EBITDA is ranked higher than
64% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.81 vs. JNJ: 13.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.90 Max: 14.1
Current: 13.28
6.7
14.1
PEG 3.47
JNJ's PEG is ranked lower than
68% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. JNJ: 3.47 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.19  Med: 1.69 Max: 26.05
Current: 3.47
1.19
26.05
Shiller P/E 23.64
JNJ's Shiller P/E is ranked higher than
76% of the 146 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.77 vs. JNJ: 23.64 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.47  Med: 20.84 Max: 29.83
Current: 23.64
15.47
29.83
Current Ratio 2.83
JNJ's Current Ratio is ranked higher than
58% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. JNJ: 2.83 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.05 Max: 2.83
Current: 2.83
1.2
2.83
Quick Ratio 2.47
JNJ's Quick Ratio is ranked higher than
62% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. JNJ: 2.47 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.70 Max: 2.47
Current: 2.47
0.94
2.47
Days Inventory 138.04
JNJ's Days Inventory is ranked lower than
63% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. JNJ: 138.04 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 105.89 Max: 137.6
Current: 138.04
100.19
137.6
Days Sales Outstanding 59.32
JNJ's Days Sales Outstanding is ranked higher than
64% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.15 vs. JNJ: 59.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.4
Current: 59.32
53.94
61.4
Days Payable 100.88
JNJ's Days Payable is ranked higher than
69% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.47 vs. JNJ: 100.88 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 100.88
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.70
JNJ's Dividend Yield is ranked higher than
76% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. JNJ: 2.70 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 1.78  Med: 2.84 Max: 3.84
Current: 2.7
1.78
3.84
Dividend Payout 0.55
JNJ's Dividend Payout is ranked lower than
71% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. JNJ: 0.55 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.42 Max: 12.5
Current: 0.55
0.29
12.5
Dividend Growth (3y) 7.10
JNJ's Dividend Growth (3y) is ranked lower than
51% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 7.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13.00 Max: 17.1
Current: 7.1
7
17.1
Forward Dividend Yield 2.84
JNJ's Forward Dividend Yield is ranked higher than
72% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. JNJ: 2.84 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.79
JNJ's Yield on cost (5-Year) is ranked higher than
74% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. JNJ: 3.79 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.5  Med: 3.98 Max: 5.39
Current: 3.79
2.5
5.39
3-Year Average Share Buyback Ratio 0.10
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. JNJ: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -0.10 Max: 2.3
Current: 0.1
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.52
JNJ's Price/Tangible Book is ranked lower than
90% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. JNJ: 12.52 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.24  Med: 10.40 Max: 18.92
Current: 12.52
6.24
18.92
Price/Projected FCF 1.65
JNJ's Price/Projected FCF is ranked higher than
68% of the 311 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. JNJ: 1.65 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.87  Med: 1.40 Max: 3.6
Current: 1.65
0.87
3.6
Price/DCF (Earnings Based) 1.93
JNJ's Price/DCF (Earnings Based) is ranked lower than
67% of the 70 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. JNJ: 1.93 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.40
JNJ's Price/Median PS Value is ranked lower than
66% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. JNJ: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 1.14 Max: 1.88
Current: 1.4
0.74
1.88
Price/Peter Lynch Fair Value 2.51
JNJ's Price/Peter Lynch Fair Value is ranked lower than
75% of the 173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. JNJ: 2.51 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.23  Med: 1.88 Max: 4.07
Current: 2.51
1.23
4.07
Price/Graham Number 3.39
JNJ's Price/Graham Number is ranked lower than
72% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. JNJ: 3.39 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 3.15 Max: 5.86
Current: 3.39
1.97
5.86
Earnings Yield (Greenblatt) (%) 6.26
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. JNJ: 6.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.5  Med: 7.70 Max: 12.9
Current: 6.26
5.5
12.9
Forward Rate of Return (Yacktman) (%) 12.37
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 323 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.36 vs. JNJ: 12.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 14.10 Max: 18.4
Current: 12.37
1.8
18.4

More Statistics

Revenue (TTM) (Mil) $70,182
EPS (TTM) $ 5.50
Beta0.88
Short Percentage of Float0.82%
52-Week Range $81.79 - 115.00
Shares Outstanding (Mil)2,750.64

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 71,875 74,772 77,107
EPS ($) 6.66 7.03 7.40
EPS without NRI ($) 6.66 7.03 7.40
EPS Growth Rate
(3Y to 5Y Estimate)
2.72%
» More Articles for NYSE:JNJ

Headlines

Articles On GuruFocus.com
'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market May 22 2016 
U.S. Stocks Trade Flat at Start of Week May 09 2016 
Johnson & Johnson a Legendary Dividend Stock May 08 2016 
UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
Johnson & Johnson Beats 1st-Quarter Expectations, Improves Guidance Apr 27 2016 
How to Know When You Can Retire With Dividend Investing Apr 13 2016 
Periodic Payments vs. Lump Sum: When's the Right Time to Pull the Plug? Apr 07 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Is Zimmer Biomet Worth the Risk? Apr 01 2016 
A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 

More From Other Websites
Johnson & Johnson to Participate in the Goldman Sachs 37th Annual Global Healthcare Conference May 25 2016
Johnson & Johnson to Participate in the Goldman Sachs 37th Annual Global Healthcare Conference May 25 2016
Celgene, JNJ, Takeda to Drive Myeloma Drug Sales May 25 2016
AGs: Pelvic mesh implants caused dire complications May 25 2016
California sues Johnson & Johnson over marketing for pelvic mesh May 24 2016
California AG sues Johnson & Johnson over marketing for pelvic mesh May 24 2016
Trump says decision to seek donations followed GOP request May 24 2016
Tuesday links: consistent declines May 24 2016
The Top 5 Johnson & Johnson Shareholders (JNJ) May 24 2016
4 Dow Members Bucking the Negative Trend May 24 2016
6:38 am Johnson & Johnson presents Phase 3 data showing that a significantly greater proportion of... May 24 2016
Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S. May 23 2016
What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)? May 23 2016
France faults Bial and Biotrial over fatal drug trial May 23 2016
Boomer Esiason Foundation Announces Collaboration with Johnson & Johnson for First-of-Its-Kind TRU... May 23 2016
Warren Buffett’s Favorite Consumer Products Stocks May 23 2016
Stocks for rainy day trades May 20 2016
Wal-Mart PT Hiked; J&J Started At Sell; ICE Is A Buy May 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)